Manufacturing Solutions for high value induced Pluripotent Stem cell products (MS-iPS)

The aim is to develop a process which can distinguish good from bad induced pluripotent stem cells (iPS cells) in terms of their differentiation capacity. Batches of iPS cells derived from multiple patient tissue samples will be analysed and grouped in terms of their ability to differentiate into the three cell lineages (endoderm, mesoderm and ectoderm). The key epigenetic marks which are the most important as distinguishing features to be able to divide them into “good” (those which can fully differentiate) versus “bad” (those which can’t) cell lines will be determined. Thus, the output of the project will be an optimised and validated key signature gene set predictive of the iPS cells differentiation capacity which would form the basis of a diagnostic tool